India Anti-Rheumatic Drug Market Size, Share, Opportunities, And Trends By Type Of Disease (Osteoarthritis, Rheumatoid Arthritis, Gout, Lupus, Others), By Drug Class (Disease-modifying Anti-Rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, JAK Inhibitor, Others), And By Sales Channel (Prescription, Over-the-counter (OTC)) - Forecasts From 2023 To 2028

The Indian anti-rheumatic drugs market is estimated to grow at a CAGR of 5.01%, reaching US$6423.254 million in 2028 from US$4561.441 million in 2021.

Indian anti-rheumatic drugs market is growing due to the rising rheumatoid arthritis prevalence, increased knowledge of other autoimmune disorders, and the rising incidence of chronic disorders like obesity and diabetes. Further, by expanding funding for medical education and training and encouraging the discovery of novel treatments for rheumatic disorders, the Indian government is acting to solve this shortfall. For instance, these medications are covered by a combination of public and commercial health insurance programs in India. Government personnel and their families have access to health insurance through the Central Government Health Scheme (CGHS), which is run by the government. Additionally, some state governments run their health insurance programs for their staff.

Rising need for antirheumatic medications

As India’s need for antirheumatic medications is rising, many pharmaceutical companies are introducing their products which is boosting the Indian anti-rheumatic drugs market expansion. For instance, Cipla, one of the top generic drug manufacturers in India, introduced the first Etanercept biosimilar in India in August 2020 under the trade name "ETACEPT" for the management of rheumatic illnesses. Adalimumab, marketed by Abbvie under the trade name Humira®, is used to treat psoriasis, ankylosing spondylitis, rheumatoid arthritis, and psoriatic arthritis.

Growing prevalence of diabetes

According to an article published in "THE HINDU," one in every six diabetics worldwide is from India. With an estimated 80 million diabetics, the country ranks second among the top 10 countries for those with the disease. In India, more than 50% of the population is at risk of developing diabetes at some point in their lives, making it a serious public health issue. Rural parts of India are also experiencing an increase in the incidence of type 2 diabetes. In India, it is estimated that 77 million adults over the age of 18 have type 2 diabetes and that almost 25 million are prediabetics (with an increased risk of developing the disease soon). If not identified and treated promptly, more than 50% of people have diabetes without being aware of it, which can have serious health consequences as per the World Health Organization.

Increasing demand for organic medications

India saw an increase in cane antirheumatic drugs imports and exports. The demand for organic antirheumatic drugs is rising in India because of the rise in the popularity of organically produced products. The majority of ayurvedic medications and potions contain organic cane antirheumatic drugs, and India is also well-known for its ayurvedic remedies. India sold 21932.591 MT of organic antirheumatic drugs in 2021–2022, according to data from the Agricultural and Processed Food Products Export Development Authority (APEDA). Manufacturers of organic antirheumatic drugs from India include Jaini International Export Private Limited, Vijayawada Chemicals, and Shree Ambika Antirheumatic Drugs Limited, among others.

Rising adoption of greenhouses for the production of fruits and vegetables

Rising consumer demand for locally sourced, fresh produce has led to increased willingness to pay for high-quality, sustainably grown fruits and vegetables. Additionally, the climate-resilient environment provided by commercial greenhouses is becoming crucial in mitigating the effects of unpredictable weather patterns caused by climate change. Technological advancements, including automation and improved crop management, are enhancing productivity and quality, attracting both investors and farmers. Greenhouses also contribute to sustainable agriculture practices, aligning with global environmental goals. The government support, in the form of incentives and policies, further amplifies the growth prospects of this segment, creating a promising future driven by economic, environmental, and consumer-related factors.

Rise in osteoarthritis cases

Osteoarthritis (OA) is a prevalent and progressively degenerative joint disorder that affects millions of people in India and is fueling the Indian anti-rheumatic drugs market. One of the primary drivers of Osteoarthritis in India is the aging population. As the country experiences a demographic shift with an increasing number of elderly individuals, the prevalence of OA has surged. Urbanization and changing lifestyles have led to a more sedentary way of living, which, in turn, contributes to the rising incidence of OA. Obesity, lack of physical activity, and poor dietary choices are all risk factors for OA development. The adoption of Western diets and reduced physical activity levels have become more common in India, exacerbating the problem.

Segmentation:

• By Type of Disease
  • Osteoarthritis
  • Rheumatoid Arthritis
  • Gout
  • Lupus
  • Others
• By Drug Class
  • Disease-modifying Anti-Rheumatic Drugs (DMARDs)
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • JAK inhibitor
  • Others
• By Sales Channel
  • Prescription
  • Over-the-counter (OTC)